CPHI/Hi Korea 2026: A Gateway to Pharmaceutical Innovation in Asia

Welcome to CPHI/Hi Korea 2026

Informa Markets Korea has kicked off the pre-registration for CPHI/Hi Korea 2026, an essential event for pharma, biopharma, and health innovation sectors. Scheduled to take place at the esteemed COEX in Seoul from August 25 to 27, this year’s edition promises to be the largest yet, covering a significant exhibition space across Halls C, E, and The Platz. The event will feature approximately 420 exhibitors from over 70 countries, showcasing the latest advancements in ingredients, products, and technological solutions to an expected audience of more than 12,000 industry professionals.

A Pillar of Innovation

As part of the global CPHI series, CPHI/Hi Korea serves as a pivotal meeting point for companies involved in pharmaceuticals, biotechnology, and nutraceuticals. This platform fosters international networking, enabling global firms to collaborate with local Korean businesses while also enhancing domestic partnerships. The event capitalizes on Korea's robust pharmaceutical manufacturing infrastructure and its rapidly advancing nutraceutical market, solidifying its status as an essential strategic hub for business ventures extending across Asia and beyond.

The event will see backing from notable government entities and industry organizations, such as the Ministry of Food and Drug Safety (MFDS), Korea Fund for Regenerative Medicine (KFRM), and many others, signifying strong institutional support for innovation and collaboration within the industry.

Expanded Conference Program

Reflecting the increasing interest from industry stakeholders, this year’s conference program will expand from four to six tracks, allowing for a broader discussion on pressing issues within the sector. A highlight will be the K-Health Conference, featuring discussions led by MFDS on regulations for personalized health functional foods. The agenda includes sessions focusing on Korea's emerging K-platform technologies, including Antibody-Drug Conjugates (ADC), Targeted Protein Degraders (TPD), and Receptor-Projection Technology (RPT), as well as the latest developments in clinical trials and GLP-1-related innovations.

In addition, the Biohealth Policy Forum, hosted by the Korea Drug Research Association (KDRA), will provide insights into policy directions and strategic priorities affecting the industry landscape. The program also aims to support startups through initiatives like the Startup Challenge and sessions geared towards the Global Build-Up Program, facilitating market entry into countries like Japan, China, Thailand, Malaysia, and the United States.

Booth Availability and Application

With growing interest, Hall E, designated for overflow demand, is nearing full capacity. Companies interested in participating are urged to secure their spots as soon as possible. Pre-registration, which grants complimentary entry to attendees, is open at the following link: CPHI/Hi Korea Pre-registration.

CPHI/Hi Korea 2026 not only promises to advance the conversation on pharmaceutical and biopharmaceutical innovation but also stands as a testament to Korea’s expanding role in the global health innovation ecosystem. Don’t miss your chance to be a part of this transformative event in the heart of Seoul, where health innovation takes center stage.